The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Ranfac sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Ranfac Corp (Ranfac) operates as a medical device company that manufactures precision medical instruments. The company’s products include percutaneous introducer, multipurpose knot pusher ligator, pneumoperitoneum insufflation needles, puncture closure device, and others. It also provides soft tissue biopsy needles, stiffening cannulas, disposable cholangiography catheters, ranfac localization system, ranfac breast marking system, ranfac breast orientation system, ranfac breast bracketing system and galactography infusion units. Ranfac also manufactures RJN bone marrow biopsy needle, snarecoil bone marrow biopsy needle, bone marrow aspiration and access needle, bone marrow kit, removable handle and bone access technology. The company provides marrow cellution, bone marrow aspiration and access needles, fat aspiration transfer system, and vacuum pressure handle. Ranfac is headquartered in Avon, Massachusetts, the US.
The key metrics of Ranfac related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Ranfac is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Ranfac.
For a detailed understanding of the performance of Ranfac, buy the report here.